Cardiology Grand Rounds
Telecast Schedule for 2008-2009 Series
Live telecasts via UW Telehealth
Services: 7:30 am
– 8:30 am, third Friday of the month
from D-209 Health Sciences
Bldg, University of Washington, Seattle, Washington.
|
Date |
Speaker |
Institute |
Title |
Host |
|
Sep 19, 2008 |
Mickey Eisenberg |
Univ. of Washington, Seattle, WA |
Surviving Cardiac Arrest: Why Some Communities Succeed and Others
Fail Learning Objectives: ·
Differentiate between patient, event, system, and therapy factors ·
Describe the frame of resuscitation ·
Define the most important factors associated with successful
resuscitation |
Page |
|
Oct 17, 2008 |
Jeffrey Probstfield and Irl Hirsch |
Univ. of Washington, Seattle, WA |
The ACCORD Trial: What did we learn about glucose control in
Type 2 Diabetes related to total mortality and macro-vascular CVD events? Learning Objectives: ·
The strategy
used in ACCORD intensive glycemia group was
associated with an increase in total mortality compared with that in the
standard gylcemia strategy. 1a. There was also
an increase in cardiovascular mortality.
1b. There was a decrease in all CVD events
(Primary outcome). ·
Good glucose
control was achieved and maintained using the proposed strategy (but not to
goal). ·
Hypoglycemia,
any single or combination of medications, was not associated with the
increase in TM. |
O’Brien |
|
Nov 21, 2008 |
Jeffrey Probstfield |
Univ. of Washington, Seattle, WA |
The ONTARGET/TRANSCEND Results: RAAS
Blockade – How Much is enough in the Prevention of CHD/CVD Events Learning
Objectives: ·
RAAS blockade ha
been established as appropriate prevention for CHDCVD Disease in those at
high risk for ASCVD. ·
Previous trials established the importance
of RAAS blockade with at least 2 ACD-Is; ONTARGET established the similarity
of blockade with an ARB in participants without LV dysfunction. ·
Blockade with a combination of ACE-Is and
ARBs does not further reduce the risk for CHD/CVD for those at high risk for
ASCVD but who do not have CHF; use of the two classes of agents together may
have risks without benefit. ·
RAAS blockade benefit is modest for those
with ASCVD using an ARB to those with ACE-1 intolerance and without LV
dysfunction |
O’Brien |
|
Dec 19, 2008 |
NO |
DECEMBER |
TELECAST |
N/A |
|
Jan 16, 2009 |
Richard Page |
U. of Washington |
Drug Therapy for AF: Is there hope on the horizon? Learning Objectives: ·
Understand the limitations of current drug therapy for AF ·
Recognize the potential benefit and options for less toxic drug
therapy ·
Anticipate the potential for new drug therapy, based on recent
clinical studies |
O’Brien |
|
Feb 20, 2009 |
Andrew Luks |
U. of Washington |
The Adult Congenital Heart Disease Patient
at High Altitude Learning Objectives: ·
Describe the basic changes in cardiac physiology upon acute ascent to
high altitude ·
Describe the main forms of high altitude illness that can affect all
travelers to high altitude ·
Outline a basic approach to evaluating patients with congenital heart
disease prior to high altitude travel |
Stout |
|
Mar 20, 2009 |
Kelley Branch |
U. of
Washington |
Cardiac Computed Tomography: The Hope,
Hype and Utility of a Burgeoning Technology Learning Objectives: ·
Describe the uses and potential complications of cardiac computed
tomography. ·
Know the most appropriate patient populations in which to use cardiac
CT. ·
Describe the current utility and the future studies of cardiac CT to
guide patient care for atherosclerosis and cardiac disease. |
Probstfield |
|
Apr 17, 2009 |
Barry Greenberg |
UCSD Medical Center |
The Cardiorenal
Syndrome Learning Objectives: ·
Describe the prevalence, risk factors and outcomes of the cardiorenal syndrome. ·
Summarize the pathophysiology of the cardiorenal syndrome. ·
Discuss new and emerging approaches to treatment. |
O’Brien |
|
May 15, 2009 |
William Weintraub |
Jefferson University and Christiana
Care Health System, Delaware |
Beyond COURAGE:
Towards More Evidence Based Coronary Care Learning Objectives: ·
Review current status of evidence in coronary care: testing and
therapeutics ·
Use of guidelines ·
Efforts to make care more evidence based ·
How to translate care into the community |
Probstfield |
|
Jun 19, 2009 |
James Caldwell |
U. of Washington |
Imaging Cardiac Sympathetic
Dysfunction Learning Objectives: ·
Have a basic understanding of the physiology of the cardiac
sympathetic myo-neural interface in heart failure
and sudden death ·
Understand how imaging can be used to evaluate the myo-neural interface ·
Understand what incremental information imaging provides in
predicting outcome and response to therapy |
O’Brien |
Revised:
6/1/09